Amylin is a 37 amino acid pancreatic peptidecostored and cosecretedwith insulin in response to nutrient intake.1,2 Uponsecretion, amylin activates receptors in the hindbrain and hypothalamusto induce satiation, and it also impacts glucose control by postprandialsuppression of nutrient-mediated glucagon secretion (not in the stateof hypoglycemia) and by delayed gastric emptying.2−5 These biological effects supportthe investigation and development of optimized amylin analogs foruse as therapeutics for weight management and diabetes. The gene discussed is IAPP; the disease is diabetes mellitus.